Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Pembrolizumab missed statistical cutoffs in hepatocellular carcinoma study

Publish date:: June 3, 2019

Key clinical point: Pembrolizumab reduced risk of death by 22% versus placebo in a phase 3 study of patients with previously treated, advanced hepatocellular carcinoma, though results did not reach statistical significance by prespecified criteria.

Major finding: For pembrolizumab vs. placebo, median overall survival was 13.9 vs. 10.6 months, and median progression-free survival was 3.0 months vs. 2.8 months.

Study details: Results of the phase 3 KEYNOTE-240 trial, which comprised 413 patients.

Disclosures: Dr. Finn reported disclosures related to AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech/Roche, Lilly, Merck, Novartis, and Pfizer.

Citation:

Finn RS et al. ASCO 2019, Abstract 4004.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,